What Asthalin Respules Treats: Main Uses and Benefits

This medication is commonly used across conditions characterized by periods of heightened symptoms in the respiratory domain. It is applied across domains where additional symptomatic support is needed, and is used in addressing symptoms that become more disruptive during flare-ups.

---

Short-Term Symptomatic Assistance During Acute Episodes

This medication is generally used to provide supportive relief during symptoms associated with acute or episodic changes, such as acute asthma attacks or exacerbations of Chronic Obstructive Pulmonary Disease (COPD). It is applied in clinical settings that involve acute or unstable symptom patterns, and may assist with addressing distressing symptoms like wheezing, chest tightness, and symptoms that create noticeable physiological strain. It provides support that helps ease the overall symptom burden, and it supports the patient during difficult episodes by easing distress.

---

Management of Chronic Disease Flares and Exercise Triggers

Asthalin Respules is relevant in contexts marked by episodic discomfort of chronic conditions, particularly when the patient experiences a sudden deterioration of symptoms. It is also applied to help manage symptoms before predictable triggers, such as physical exertion (exercise-induced bronchospasm). This use contributes to improved comfort during periods of heightened symptoms, may assist with maintaining functional stability, and contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Respiratory Symptom Clusters

Asthalin Respules is relevant for easing symptoms related to heightened physiological activity. It is commonly used when short-term symptomatic assistance is needed to address symptom clusters that may become intense or disruptive.

Asthalin Respules (salbutamol) is subject to specific regulatory eligibility rules that define who is allowed to use the medicine and who must not use it.

Contraindicated Populations

• Hypersensitivity: The medicine is strictly contraindicated in patients with a history of allergy or hypersensitivity to salbutamol or any of the product’s components.
• Obstetrics: Inhaled salbutamol preparations are not appropriate for managing threatened abortion or uncomplicated premature labor.

Age-Related Eligibility

Age Group	Eligibility Status (Regulatory Basis)
Adults & Adolescents	Indicated for use (12 years and over) [1.4]
Children	Indicated for use (4 to 11 years) [2.2]
Infants	Clinical efficacy is uncertain (under 18 months) [2.2]

Condition-Specific Cautions

Regulatory documents mandate use with caution if the patient has certain pre-existing conditions, including serious cardiac disorders (such as severe heart failure, coronary heart disease, or recent myocardial infarction) and endocrine/metabolic disorders (such as uncontrolled diabetes mellitus or hyperthyroidism) [1.1, 2.2].

Pregnancy and Lactation

While use during pregnancy to treat asthma may be considered, the product is not recommended for nursing mothers unless the benefit is judged to outweigh the potential risk to the infant, as salbutamol is likely secreted in breast milk [2.2].

Interactions with other medicines and products

Asthalin Respules (Salbutamol) interacts with several classes of medicines, primarily through pharmacodynamic potentiation or antagonism, as documented in official prescribing information.

---

Prohibited and High-Risk Combinations

Co-administration is generally not recommended for non-selective beta-receptor blocking agents (e.g., Propranolol). These medicines can directly oppose the bronchodilating effect of Salbutamol and pose a risk of severe bronchospasm in patients with asthma. Other sympathomimetic aerosol bronchodilators should be avoided due to the documented potential for excessive cardiovascular stimulation.

Pharmacodynamic and Metabolic Interactions

The regulatory label highlights significant interaction risks with agents that affect the cardiovascular system or electrolyte balance:

• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the effect of Salbutamol on the vascular system. This risk is subject to a mandatory restriction: Salbutamol should be used with extreme caution within two weeks of discontinuing these agents.
• Diuretics (non-potassium-sparing), Glucocorticoids/Steroids, and Xanthine Derivatives (e.g., Theophylline) increase the risk of hypokalaemia (low potassium levels) when co-administered due to an additive effect.
• Salbutamol has been documented to cause a decrease in the serum concentration of Digoxin (a cardiac glycoside).
• A risk of acute angle closure glaucoma has been reported when Salbutamol is nebulized concurrently with anticholinergic agents (e.g., Ipratropium Bromide). This constraint is specific to the nebulized route of administration.

How Asthalin Respules Works

Asthalin Respules contains the active substance salbutamol, which exerts its pharmacologic effect by targeting the involuntary nervous system. Its mechanism is defined by a highly selective interaction with specific cellular targets in the respiratory tract, resulting in direct physiological changes.

---

Targeting beta2-Adrenergic Receptors

Salbutamol functions as a selective agonist (activator) of the beta2-adrenergic receptors, which are localized predominantly on the smooth muscle cells lining the bronchial passages. This interaction modulates a key signaling pathway associated with sympathetic system activation. The binding of salbutamol directly influences the functional state and contractility of the bronchial smooth muscle.

---

Initiating Intracellular Relaxation Cascade

The binding to the beta2-receptor initiates an intracellular mechanistic cascade by activating the enzyme adenylyl cyclase. This activation increases the intracellular concentration of the second messenger, cyclic adenosine monophosphate (cAMP). The subsequent rise in cAMP modifies early molecular steps within the smooth muscle cells, leading to a reduction in the concentration of intracellular calcium ions. This reduction in calcium ultimately causes the relaxation of the contracted bronchial musculature.

Official Administration Guidelines for Asthalin Respules

Asthalin Respules are a solution for inhalation use only and must be administered through the mouth via a suitable nebuliser, under the direction of a physician. The solution must not be injected or swallowed.

Dosing and Frequency

The typical starting dose for Adults (including the elderly) is 2.5 mg as a single dose, which may be increased to 5 mg. This treatment can be repeated up to four times a day in the routine management of chronic bronchospasm. For severe airways obstruction in a hospital setting, doses of up to 40 mg per day may be administered under strict medical supervision.

For Children aged 4 to 11 years, the dose is generally 2.5 mg to 5 mg up to four times a day. The clinical effectiveness of nebulised salbutamol in infants under 18 months remains uncertain, and supplemental oxygen therapy should be considered due to the risk of transient hypoxia.

Procedural Steps

1. Asthalin Respules are generally intended for use undiluted. If a prolonged delivery time (exceeding 10 minutes) is necessary, the solution may be diluted with sterile normal saline.
2. Twist off the top of the respule/transpule and squeeze the contents into the reservoir of the nebuliser chamber.
3. Use the content of each respule as soon as possible after opening, and discard any solution left in the ampoule.
4. The patient should be adequately instructed to inhale the medicine slowly and deeply and warned not to let the solution or mist enter the eye.

Patients must not increase the dose or frequency of administration without medical advice, as this may indicate a worsening of the underlying condition.

Research evidence / Overview of studies for Asthalin Respules

Overview of Clinical Evaluation for Acute Symptom Relief

The foundation of the research involves numerous controlled trials that explored short-term outcomes related to the exploration of acute respiratory events. Studies were conducted during periods of increased symptom activity in patients with conditions like asthma attacks and sudden flare-ups of Chronic Obstructive Pulmonary Disease (COPD). Researchers primarily examined physical outcomes related to systemic or functional imbalance, specifically monitoring objective measures of lung function like Forced Expiratory Volume in 1 second ( FEV1) and clinical parameters such as respiratory rates.

Findings describe group patterns observed in these acute settings, focusing on the measurable changes in lung function parameters over defined time intervals in the observed populations. Certain observational studies described a statistical association where high-frequency usage of this drug, monitored over extended periods, was observed in some studies to be associated with patterns of increased event frequency.

---

Research on Preventative Use Before Physical Exertion

Research has also studied this solution in contexts involving predictable triggers, such as physical exertion. Studies examining the potential for Exercise-Induced Bronchospasm (EIB) were conducted as controlled clinical trials, where subjects received the solution prior to undergoing a standardized exercise challenge. The studies monitored outcomes related to functional imbalance, with researchers focusing on the precise measurement of the fall in FEV1 after the exercise challenge.

Findings describe patterns related to the duration of the measured effect that was observable. However, studies also described that consistent, regular administration over a period of weeks was associated with an altered measurable response to the exercise challenge.

---

Long-Term Evidence and Follow-up Durations

Most clinical evaluation was designed to explore the pharmacodynamic profile of the solution, meaning the primary focus was on short-term relief assessed within minutes or hours. Evidence exploring the duration of the measured observation over months or years is limited.

Research that extends to longer follow-up durations often takes the form of observational studies or analyses of patient registries. These studies track patterns of use, and data show patterns related to how frequently patients use this short-acting bronchodilator medicine. Long-term effects, such as the overall impact on the progression of chronic lung disease, are not fully established by these short-term efficacy trials.

---

Evidence in Specific Patient Groups (Special Populations)

Studies have been conducted across a range of ages, including clinical trials focusing on children (aged two years and older) who present with acute asthma exacerbations. Research has also studied the solution in patients across the disease severity spectrum of COPD, including those with moderate-to-severe conditions.

---

Known Evidence Gaps and Areas of Scientific Uncertainty

Research provides insight into short-term changes, but the evidence quality varies across studies, and several areas remain uncharacterized. Follow-up durations were limited in many of the core efficacy trials, meaning long-term outcomes are not well characterized.

Comparative evidence is lacking for certain scenarios. For example, there is limited information comparing the overall clinical effects and patient-reported outcomes of the nebulizer solution directly against alternative short-acting bronchodilator inhalation devices, especially in non-emergency settings.

Common questions about Asthalin Respules (FAQ)

Q: Is Asthalin Respules the same as a regular Asthalin inhaler?

A: Asthalin Respules is a solution for inhalation via a nebulizer. While it contains the same active ingredient (salbutamol) as regular Asthalin inhalers (which are often dry powder or metered-dose inhalers), the product's formulation and the device used to deliver it are different. This means they are administered in different ways for different clinical situations.

Q: Why is Asthalin Respules given as a solution for nebulization?

A: The official product information indicates that this formulation is used for the management of chronic bronchospasm and is also often used for the treatment of acute severe asthma. Nebulized delivery allows for the administration of a higher dose, which is sometimes required in a clinical setting to treat sudden, severe breathing difficulty.

Q: Can Asthalin Respules be used for a common cough or cold?

A: Asthalin Respules is officially indicated for the treatment of specific respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD). Regulatory documents do not list use for a common cough or cold as a stated indication.

Q: What should I do if I forget to use the respule when scheduled?

A: According to patient information materials, if a dose is missed, taking it as soon as it is remembered is commonly advised. If it is nearly time for the next scheduled dose, skipping the missed dose and returning to the regular schedule is described. It is important not to take a double dose to make up for a missed one.

Q: Can Asthalin Respules be used long-term?

A: Official warnings note that an increased frequency of use may be a sign that your underlying respiratory condition is getting worse. High-frequency use is described as an important factor for medical review, as it has been associated with patterns of increased adverse events. It is designed primarily as a short-acting, 'as-needed' treatment.

Q: Can Asthalin Respules be used during pregnancy?

A: Official documents state that the use of salbutamol during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus. The medicine is also specifically contraindicated (not allowed) for use to stop a threatened abortion.

Q: Are there any restrictions on driving or operating machinery while using this medicine?

A: The official product information generally reports that the medicine has no known effect on the ability to drive or operate machines. However, because it can cause side effects like tremor or dizziness, if effects like tremor or dizziness occur, official information advises caution regarding driving or operating machinery.

Q: Do you need a prescription for Asthalin Respules?

A: Asthalin Respules, which contains the active substance salbutamol, is classified as a medicine that requires a prescription in most countries. This is due to the potential risks and the need for medical supervision and guidance when treating respiratory conditions.

Q: Why is it important to clean the nebulizer after using Asthalin Respules?

A: Although regulatory labels for the drug itself may not list cleaning instructions, patient information materials often advise cleaning the nebulizer after each use. This is crucial for device hygiene and ensures the nebulizer continues to function correctly and deliver the proper dose of medicine.

Q: What are the signs that Asthalin Respules is working?

A: The medicine works as a bronchodilator by relaxing the muscles around the airways. This action is expected to lead to the relief of acute symptoms like wheezing, shortness of breath, or chest tightness, often starting within a few minutes due to its quick onset.

Q: Can Asthalin Respules be mixed with other nebulizer solutions?

A: The respule solution is primarily intended to be used undiluted. It may be diluted with sterile normal saline if a longer administration time is required. Official prescribing information also notes that co-nebulization with certain other drug classes, such as anticholinergic agents, is noted to carry a specific risk and is advised to be used with caution.

Q: What happens if Asthalin Respules is accidentally swallowed?

A: Official guidelines specify that the solution is for inhalation only and should not be swallowed. Accidental ingestion may lead to systemic effects similar to an overdose. These effects can include tachycardia (fast heart rate), tremor (shaking), and potentially dangerous drops in potassium levels (hypokalaemia). These systemic effects are serious and require immediate medical evaluation.

Q: Does Asthalin Respules interact with medicines for depression or anxiety?

A: Yes, official documents advise caution when using Asthalin Respules alongside specific classes of medicines used for depression or anxiety, such as Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs). These combinations may potentiate (increase) the effects of salbutamol on the vascular system.

Q: Can a patient become dependent on Asthalin Respules?

A: Official warnings state that increasing the dose or frequency of use may be a sign of worsening disease. However, the medicine is generally a short-acting bronchodilator and is not classified as habit-forming in official therapeutic documents.

Q: Why is it called a 'rescue' medicine by some people?

A: This term is commonly used by patients and healthcare professionals to describe the medication's therapeutic role. It is due to its classification as a short-acting bronchodilator (SABA), which provides rapid relief (often within five minutes) during an acute asthma attack or sudden breathing difficulty.

Q: Are there different types of nebulizers recommended for Asthalin Respules?

A: The official administration instructions specify that the solution must be used via a suitable nebulizer. While regulatory labels do not specify brand names, the device is required to be appropriate for administering inhalation solution as guided by a healthcare provider.

Q: What is the official information regarding use while breastfeeding?

A: Official prescribing information notes that salbutamol is likely secreted in breast milk. Official information indicates that its use requires careful consideration, and the drug should be administered only if the expected benefit to the mother is determined to outweigh any potential risk to the baby.

Q: Does Asthalin Respules affect blood sugar levels?

A: Yes, the product information advises caution for patients with Diabetes Mellitus. Salbutamol is known to have the potential to cause a temporary increase in blood sugar levels. Patients with Diabetes Mellitus may require monitoring of blood sugar levels.

Q: What is the maximum number of respules that studies have examined?

A: Regulatory dosing guidelines cite that in cases of severe airways obstruction administered under strict medical supervision in a hospital setting, the maximum dose administered to adults may be up to 40 mg per day. This is the equivalent of a substantial number of respules.

Q: Is Asthalin Respules the same active ingredient as Ventolin?

A: Yes, the official product information confirms that Asthalin Respules and the brand-name medicine Ventolin both contain the same active ingredient, which is salbutamol.

Q: Is there any research on the use of Asthalin Respules in older adults?

A: Official dosing guidelines provide a typical starting dose specifically for Adults (including the elderly). This indicates that the medicine has been evaluated for safe and effective use in this general population group.

Q: Can Asthalin Respules make me feel tired or drowsy?

A: Official lists of side effects do not typically include fatigue or drowsiness as common reactions. Any effect on alertness would most likely be related to the known side effects, such as a fast heart rate or tremor.

Q: Is the medication designed to prevent future attacks?

A: No. Official documents confirm that salbutamol is a short-acting bronchodilator (SABA). Its design and therapeutic role are focused on providing acute symptom relief during an episode, rather than the long-term prevention of future attacks.

Q: Is Asthalin Respules used only for asthma?

A: No. According to the official indications, Asthalin Respules is used for the treatment of acute severe asthma and is also indicated for the routine management of chronic bronchospasm in conditions like Chronic Obstructive Pulmonary Disease (COPD).

Storage and Disposal of Asthalin Respules

Asthalin Respules (salbutamol sulfate) must be stored strictly according to regulatory mandates to ensure stability.

---

Official Storage Conditions

Scope Element	Official Regulatory Requirement
Temperature Range	Store below 25 C or below 30 C; avoid excessive heat.
Protection Requirements	Must be protected from light and do not freeze.
Packaging Rules	Keep Respules in their original foil pouch until use.
Child Safety	Must be kept out of the sight and reach of children.

---

Stability and Disposal

The Respule solution is for immediate use only once opened, and any unused solution remaining in the nebulizer must be discarded. Disposal of unused or expired medicine must follow local regulations; it should not be thrown into wastewater or household trash.